Monarch Medical Research (MMR) was established to facilitate multi-specialty Pharmaceutical Clinical Research Trials throughout Hampton Roads, Virginia. Monarch represents a core team of experienced clinical research physicians and coordinators. MMR-managed projects represent the best in sponsored clinical research. Our goal has been to produce quality data with emphasis on efficiency and speed to meet the needs of the pharmaceutical industry’s "faster time to market" while assuring patient safety and adherence to GCP and regulatory guidelines. Successful patient recruitment methods have resulted in repeatedly meeting and exceeding enrollment goals.

Monarch Medical Research has over ten years of experience conducting Phase I, II, III and IV pediatric and adult clinical trials. MMR represents multiple adult and pediatric subspecialties, with a strong track record in CNS research from migraine and ADD/ADHD to epilepsy in neurology; and from anxiety to depression in psychiatry.

Monarch Medical Research has enjoyed working with the following sponsors and CRO's to conduct clinical trials:

Abbott Laboratories Advanced Biomedical Research ALZA AstraZeneca Bristol-Myers Squibb Celgene Corporation, Inc. Cephalon, Inc. Covance Eli Lilly and Company GlaxoWellcome Glaxo Smith-Kline Hoffman-La Roche, Inc. INC Research Ingenix Pharmaceutical Services Johnson & Johnson Krannert Institute Merck and Company MEDEVA Mylan Pharmaceuticals NIH

Novartis Pharmaceuticals Organon Ortho McNeil Pharmaceutical Research Parke-Davis Pharmaceutical Research PAREXEL Pfizer Quintiles PPD Development Pharmaceutical Research Associates (PRA, Inc.) Premier Research Worldwide R.W. Johnson Pharmaceutical Research Institute Shire Laboratories, Inc. Smith Kline Beecham Schwarz UCB Pharma, Inc. Whitehall-Robins Wyeth-Ayerst Research Zeneca Pharmaceuticals

MMR is affiliated with a 60 person pediatric subspecialty group and the areas only free standing tertiary hospital, providing access to a wide range of primary and subspecialties. Our research facilities are fully equipped with the most current communication and research technologies.

Monarch Medical Research’s investigators are among the best medical doctors in the area, dedicated to patient safety and education, in conjunction with the advancement of science. All investigators take part in MMR’s formal training as well as training from outside sources to ensure that we are always up-to-date with the latest research information.

Monarch Medical Research’s full-time professional research and support staff begin their careers with MMR with an extensive in-house training program and continuously undergo formalized training throughout to ensure that we are in compliance with ever-changing FDA, ICH and GCP requirements. MMR has board certified RN’s and ACRP certified clinical research coordinators. Monarch Medical Research’s research team is made up of highly motivated and focused clinical research coordinators trained to manage all aspects of clinical trials, regulatory personnel trained specifically to manage IRB submissions and correspondence, and an excellent support staff.

The Tidewater area represents a population of 1.5 million who receive their medical care from providers in the Monarch drawing area. We experience little of the institutional shifting so common to major cities. This regional identification and a very positive attitude toward research contribute to Monarch's very successful enrollment and completion rates.

Detailed demographic information is available on: Alzheimer’s Disease, Autism, Parkinson’s Disease, ALS, MS. Migraine, Movement Disorders, Epilepsy, ADD/ADHD, Bipolar, Anxiety and Depression.

CenterWatch is listing the following trials that are actively recruiting patients at this center.

• A Multicenter Double-blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study in Children and Adolescents with Autistic Disorder
• A Randomized, Open-Label, Multicenter Study with Open-Label Extension of the Pharmacokinetics and Safety of an Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy in Infants (Aged 1 to 24 Months, Inclusive) With Refractory Partial-Onset Seizures
• An Investigational drug for Children with Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia
• An Investigational Product for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children
• Child Studies: Attention Deficit Hyperactivity Disorder
• Consequences of Prolonged Febrile Seizures in Children
• NIH Study to Identify the Optimal Anticonvulsant (ie, the AED with the highest rate of seizure control and lowest incidence of treatment limiting toxicity) used for the initial treatment of children with Childhood Absence Epilepsy (CAE).

For more information, please contact:

Sharon Krick Cole, RN,BSN,CCRC
Clinical Research Director
Monarch Medical Research
850 Southampton Avenue
Norfolk, VA 23510 USA
Phone: 757-668-9932
Fax: 757-668-8926
E-mail:

If you are interested in contacting this center to discuss placing a clinical trial there, please complete and send the E-mail form below. A representative from the research center will then follow up with you.

Name:
Address:
City:
State:
Zip:
Phone:
Email address:
Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

Last updated on August 21, 2008